CyBio: Tularik GmbH awards contract worth millions for Screen-machine and replicator
Tularik Inc., founded in San Francisco in 1991 and listed on NASDAQ since December 1999, has expanded its operations into Europe with Tularik GmbH in the Regensburg BioPark. The company is a forerunner in the field of gene control. The goal is to discover and develop medications that can activate or inhibit areas of DNA that are responsible for the development of diseases such as cancer, diabetes or immune system disorders. These new medications are highly effective, because they act specifically where many diseases originate: on the defective development of certain hereditary traits. In order to implement various research projects, Tularik has entered into strategic alliances with leading pharmaceutical firms, such as Knoll AG, Roche Bioscience and Japan Tobacco.
Tularik is expecting the CyBiTM-Screen-machine and the replicator for sample preparation to speed up medical active substance searches substantially, allowing the firm to add promising new patents to the more than 120 it has registered so far.
Most read news
Other news from the department business & finance
Get the chemical industry in your inbox
From now on, don't miss a thing: Our newsletter for the chemical industry, analytics, lab technology and process engineering brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.